HDAC6 and lung cancer: Upregulated EGFR activity is a major drug target for the treatment of solid tumours and the microtubule-dependent transport of EGFR endosomal vesicles by α-tubulin acetylation links HDAC6 to the pathogenesis of prostate, pancreatic, and lung cancer cells [13].